Author | Detlev Hecker, PhD

Articles

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

April 01, 1997

ByHans-Joachim Lück, MD

Andreas Du Bois, MD, PhD

Christoph Thomssen, MD, PhD

Björn Lisboa, MD, PhD

Michael Untch, MD, PhD

Günther Köhler, MD, PhD

Detlev Hecker, PhD

Klaus Diergarten, MD

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in